| 000 | 01762 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250514075925.0 | ||
| 264 | 0 | _c20031125 | |
| 008 | 200311s 0 0 eng d | ||
| 022 | _a0149-2918 | ||
| 024 | 7 |
_a10.1016/s0149-2918(03)80208-4 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRodby, Roger A | |
| 245 | 0 | 0 |
_aThe cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy. _h[electronic resource] |
| 260 |
_bClinical therapeutics _cJul 2003 |
||
| 300 |
_a2102-19 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAmlodipine _xeconomics |
| 650 | 0 | 4 |
_aAntihypertensive Agents _xeconomics |
| 650 | 0 | 4 |
_aBiphenyl Compounds _xeconomics |
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 |
_aDiabetes Mellitus, Type 2 _xcomplications |
| 650 | 0 | 4 |
_aDiabetic Nephropathies _xcomplications |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHealth Care Costs |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypertension _xcomplications |
| 650 | 0 | 4 | _aIrbesartan |
| 650 | 0 | 4 | _aLife Expectancy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMarkov Chains |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aTetrazoles _xeconomics |
| 700 | 1 | _aChiou, Chion Fang | |
| 700 | 1 | _aBorenstein, Jeff | |
| 700 | 1 | _aSmitten, Allison | |
| 700 | 1 | _aSengupta, Nishan | |
| 700 | 1 | _aPalmer, Andrew J | |
| 700 | 1 | _aRoze, Stéphane | |
| 700 | 1 | _aAnnemans, Lieven | |
| 700 | 1 | _aSimon, Teresa A | |
| 700 | 1 | _aChen, Roland S | |
| 700 | 1 | _aLewis, Edmund J | |
| 773 | 0 |
_tClinical therapeutics _gvol. 25 _gno. 7 _gp. 2102-19 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0149-2918(03)80208-4 _zAvailable from publisher's website |
| 999 |
_c12716492 _d12716492 |
||